The Chronicle
dukechronicle.com
Researchers uncover how leukemia infiltrates the brain By Michael Lee Contributing Reporter
Acute lymphoblastic leukemia can wreak havoc when it spreads to the brain—but until recent Duke research, no one had shown how ALL manages to do so. The research team discovered that ALL cancer cells have a special receptor allowing them to bind a protein on blood vessels that lead directly to the central nervous system. This allows the cancer cells to infiltrate the blood vessels and head straight for the brain. “The ALL cells have a high propensity to go into the central nervous system,” said Dorothy Sipkins, associate professor of medicine and senior author of the paper. “They want to be there for some reason and what we were trying to understand is how.” Sipkins likened the process to a firehouse, in which the top floor of the firehouse is the bone marrow and the bottom floor is the central nervous system. The fireman’s pole is a blood vessel on which the ALL cell easily and directly slides down. In the United States alone, there have been about 6,000 cases of ALL and approximately 1,500 resulting deaths in 2018, according to the American Cancer Society website. ALL is a deadly type of cancer that occurs when white blood cells in the body begin to grow uncontrollably and rapidly. For more than half of patients with ALL, the cancer affects the brain by invading the central nervous system and makes recovery prospects much lower, Sipkins mentioned. For decades, no one was able to identify how cancer cells enter the central nervous system. Sipkins and her lab spent years of work trying to understand this mechanism. This deadly invasion of the nervous system was always thought to be caused by the cancer cells crossing the blood brain barrier, which acts to protect the brain from harmful substances. “We tried by many means to identify the molecular
mechanisms that could mediate that process,” she said. “Every time we looked for that, we failed to find any evidence of the cells entering the central nervous system via that type of route.” After years of work, Sipkins’ lab had to re-evaluate and take a hard turn. The discovery finally came when the lab was testing a drug in collaboration with a drug company. After administering the medication to mice that had ALL, Sipkins noticed that the only reason the mice were surviving longer was because they were not developing a central nervous system disease. How exactly the disease did not develop in the central nervous system still remained a mystery. Sipkins noticed that the drug was not effective in completely eliminating the disease in the bone marrow—where the disease originates—but also knew that it could not penetrate the central nervous system to fight disease there. From these observations, her team was able to deduce that the drug was preventing the cancer cells from entering the central nervous system altogether. “We thought, ‘Wow, we finally have a tool to try and untangle this mystery,’” Sipkins said. Despite the headway, the main issue still remains unsolved. “The hardest part was finding how these cells actually get in from the bone marrow to the central nervous system,” said Trevor Price, a postdoctoral scholar in the Sipkins Lab and contributing author of the paper. Currently, patients with ALL must go through aggressive treatments with great toxicity, but Sipkins said this new discovery could greatly minimize that. She admitted, however, that there is still a long road ahead and that she can’t overstate things. Nevertheless, this paper is definitely a potential step forward in a long process. “The ultimate goal is to develop a therapeutic treatment that could specifically target this mechanism that would prevent these cells from migrating from bone marrow to central nervous system,” Sipkins said.
BE THE FIRST TO KNOW
ABOUT NEW ARRIVALS, SPECIAL COLLECTIONS, THE LATEST IN TECHNOLOGY, SALES EVENTS, AND MORE.
MONDAY, SEPTEMBER 10, 2018 | 3
Duke profs take sides in Harvard admissions lawsuit By Sam Kim Senior News Reporter
An admissions lawsuit is rattling Harvard, and professors at Duke are taking sides. The lawsuit claims that Harvard discriminated against AsianAmerican applicants in its admissions practices by giving them lower personality ratings as part of a soft quota—an accusation that that cites the expert testimony of Peter Arcidiacono, a professor of economics at Duke. Two other professors, Walter Dellinger and Helen Ladd, have submitted briefs defending Harvard by questioning the suit’s legitimacy or by supporting the university’s own numbercrunching methods. The trial is scheduled to begin Oct. 15, 2018. Peter Arcidiacono Arcidiacono is the labor economist hired by Students for Fair Admissions (SFFA), the anti-affirmative action group bringing the lawsuit, to analyze Harvard’s admissions data. According to his analysis, Asian-Americans scored higher than other applicants on grades, test scores and extracurricular activities. But they consistently received lower marks on the “personal rating,” which includes traits like “positive personality,” “kindness” and “likability.” “The difference is notable because similar ratings by teachers, guidance counselors and alumni interviewers do not show nearly as much of a difference between [Asian-American and white applicants],” Arcidiacono stated in court documents. This penalty against Asian-Americans hurt their chances of admission to Harvard, according to his analysis. Legacy and athlete admits could not explain the disparity. Arcidiacono has been controversial in the past. In 2012, he co-authored a study arguing that black and legacy students were See HARVARD on Page 4
IT’S SO CREAMY
SIGN UP! The University Store Duke eSTORE Duke Technology Center Gothic Bookshop News & Events Medical Center Store Secret Sales Class of 2022
To sign up, visit our website at www.dukestores.duke.edu and click on the BTFTK icon on the left. Our Privacy Policy: We respect your right to personal privacy. We promise to use this subscription service for the express purpose of keeping you informed of only those services that you have requested. Your personal information will not be disclosed to any third parties. We hope you will find our e-mails of benefit. We promise to keep them informative and to-the-point. You will have the option of unsubscribing from this service with each e-mail campaign.
OPERATION: Stores Administration
PUBLICATION: Chronicle
MENU SAMPLING Old School Veggie Burrito Regular Chicken Burrito Cheese Quesadilla Chicken Quesadilla Chips & Salsa
$2.86 $5.65 $1.41 $3.59 $2.06
1920 1/2 Perry St. @ Ninth Street Just a block from East Campus